vs
雷诺士国际（LII）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
雷诺士国际的季度营收约是Revvity的1.5倍（$1.2B vs $772.1M），雷诺士国际净利率更高（13.6% vs 12.7%，领先0.8%），Revvity同比增速更快（5.9% vs -11.2%），雷诺士国际自由现金流更多（$376.7M vs $161.8M），过去两年Revvity的营收复合增速更高（9.0% vs 6.8%）
雷诺士国际是美国知名的暖通空调（HVAC）及制冷领域气候控制产品供应商，总部位于得克萨斯州理查森。公司在墨西哥萨尔蒂约、美国爱荷华州马歇尔敦、南卡罗来纳州奥兰治堡设有核心生产基地，1904年收购公司的诺里斯家族后裔约翰·W·诺里斯三世持有其9.8%的股份。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
LII vs RVTY — 直观对比
营收规模更大
LII
是对方的1.5倍
$772.1M
营收增速更快
RVTY
高出17.0%
-11.2%
净利率更高
LII
高出0.8%
12.7%
自由现金流更多
LII
多$214.9M
$161.8M
两年增速更快
RVTY
近两年复合增速
6.8%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $1.2B | $772.1M |
| 净利润 | $162.1M | $98.4M |
| 毛利率 | 34.7% | — |
| 营业利润率 | 18.6% | 14.5% |
| 净利率 | 13.6% | 12.7% |
| 营收同比 | -11.2% | 5.9% |
| 净利润同比 | -18.0% | 3.9% |
| 每股收益（稀释后） | $4.62 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收LIIRVTY
| Q4 25 | $1.2B | $772.1M | ||
| Q3 25 | $1.4B | $698.9M | ||
| Q2 25 | $1.5B | $720.3M | ||
| Q1 25 | $1.1B | $664.8M | ||
| Q4 24 | $1.3B | $729.4M | ||
| Q3 24 | $1.5B | $684.0M | ||
| Q2 24 | $1.5B | $691.7M | ||
| Q1 24 | $1.0B | $649.9M |
净利润LIIRVTY
| Q4 25 | $162.1M | $98.4M | ||
| Q3 25 | $245.8M | $46.7M | ||
| Q2 25 | $277.6M | $53.9M | ||
| Q1 25 | $120.3M | $42.2M | ||
| Q4 24 | $197.7M | $94.6M | ||
| Q3 24 | $239.0M | $94.4M | ||
| Q2 24 | $245.9M | $55.4M | ||
| Q1 24 | $124.3M | $26.0M |
毛利率LIIRVTY
| Q4 25 | 34.7% | — | ||
| Q3 25 | 32.8% | 53.6% | ||
| Q2 25 | 34.8% | 54.5% | ||
| Q1 25 | 30.6% | 56.5% | ||
| Q4 24 | 33.9% | — | ||
| Q3 24 | 32.6% | 56.3% | ||
| Q2 24 | 33.6% | 55.7% | ||
| Q1 24 | 32.5% | 54.6% |
营业利润率LIIRVTY
| Q4 25 | 18.6% | 14.5% | ||
| Q3 25 | 21.7% | 11.7% | ||
| Q2 25 | 23.6% | 12.6% | ||
| Q1 25 | 14.5% | 10.9% | ||
| Q4 24 | 18.2% | 16.3% | ||
| Q3 24 | 20.2% | 14.3% | ||
| Q2 24 | 22.1% | 12.4% | ||
| Q1 24 | 15.9% | 6.8% |
净利率LIIRVTY
| Q4 25 | 13.6% | 12.7% | ||
| Q3 25 | 17.2% | 6.7% | ||
| Q2 25 | 18.5% | 7.5% | ||
| Q1 25 | 11.2% | 6.4% | ||
| Q4 24 | 14.7% | 13.0% | ||
| Q3 24 | 16.0% | 13.8% | ||
| Q2 24 | 16.9% | 8.0% | ||
| Q1 24 | 11.9% | 4.0% |
每股收益（稀释后）LIIRVTY
| Q4 25 | $4.62 | $0.86 | ||
| Q3 25 | $6.98 | $0.40 | ||
| Q2 25 | $7.82 | $0.46 | ||
| Q1 25 | $3.37 | $0.35 | ||
| Q4 24 | $5.52 | $0.77 | ||
| Q3 24 | $6.68 | $0.77 | ||
| Q2 24 | $6.87 | $0.45 | ||
| Q1 24 | $3.47 | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $34.7M | $919.9M |
| 总债务越低越好 | $1.1B | — |
| 股东权益账面价值 | $1.2B | $7.3B |
| 总资产 | $4.1B | $12.2B |
| 负债/权益比越低杠杆越低 | 0.98× | — |
8季度趋势，按日历期对齐
现金及短期投资LIIRVTY
| Q4 25 | $34.7M | $919.9M | ||
| Q3 25 | $59.2M | $931.4M | ||
| Q2 25 | $55.1M | $991.8M | ||
| Q1 25 | $222.9M | $1.1B | ||
| Q4 24 | $422.3M | $1.2B | ||
| Q3 24 | $255.7M | $1.2B | ||
| Q2 24 | $57.8M | $2.0B | ||
| Q1 24 | $57.6M | $1.7B |
总债务LIIRVTY
| Q4 25 | $1.1B | — | ||
| Q3 25 | $838.2M | — | ||
| Q2 25 | $835.7M | — | ||
| Q1 25 | $834.2M | — | ||
| Q4 24 | $833.1M | — | ||
| Q3 24 | $827.6M | — | ||
| Q2 24 | $1.1B | — | ||
| Q1 24 | $1.2B | — |
股东权益LIIRVTY
| Q4 25 | $1.2B | $7.3B | ||
| Q3 25 | $1.1B | $7.4B | ||
| Q2 25 | $900.5M | $7.6B | ||
| Q1 25 | $852.5M | $7.6B | ||
| Q4 24 | $850.2M | $7.7B | ||
| Q3 24 | $754.0M | $7.9B | ||
| Q2 24 | $577.4M | $7.9B | ||
| Q1 24 | $368.8M | $7.8B |
总资产LIIRVTY
| Q4 25 | $4.1B | $12.2B | ||
| Q3 25 | $3.5B | $12.1B | ||
| Q2 25 | $3.7B | $12.4B | ||
| Q1 25 | $3.5B | $12.4B | ||
| Q4 24 | $3.5B | $12.4B | ||
| Q3 24 | $3.3B | $12.8B | ||
| Q2 24 | $3.2B | $13.4B | ||
| Q1 24 | $3.0B | $13.4B |
负债/权益比LIIRVTY
| Q4 25 | 0.98× | — | ||
| Q3 25 | 0.78× | — | ||
| Q2 25 | 0.93× | — | ||
| Q1 25 | 0.98× | — | ||
| Q4 24 | 0.98× | — | ||
| Q3 24 | 1.10× | — | ||
| Q2 24 | 1.95× | — | ||
| Q1 24 | 3.13× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $405.9M | $182.0M |
| 自由现金流经营现金流 - 资本支出 | $376.7M | $161.8M |
| 自由现金流率自由现金流/营收 | 31.5% | 21.0% |
| 资本支出强度资本支出/营收 | 2.4% | 2.6% |
| 现金转化率经营现金流/净利润 | 2.50× | 1.85× |
| 过去12个月自由现金流最近4个季度 | $638.8M | $509.4M |
8季度趋势，按日历期对齐
经营现金流LIIRVTY
| Q4 25 | $405.9M | $182.0M | ||
| Q3 25 | $300.7M | $138.5M | ||
| Q2 25 | $86.8M | $134.3M | ||
| Q1 25 | $-35.8M | $128.2M | ||
| Q4 24 | $332.4M | $174.2M | ||
| Q3 24 | $452.1M | $147.9M | ||
| Q2 24 | $184.0M | $158.6M | ||
| Q1 24 | $-22.8M | $147.6M |
自由现金流LIIRVTY
| Q4 25 | $376.7M | $161.8M | ||
| Q3 25 | $265.1M | $120.0M | ||
| Q2 25 | $58.3M | $115.5M | ||
| Q1 25 | $-61.3M | $112.2M | ||
| Q4 24 | $272.2M | $149.8M | ||
| Q3 24 | $410.9M | $125.6M | ||
| Q2 24 | $151.3M | $136.6M | ||
| Q1 24 | $-52.3M | $129.7M |
自由现金流率LIIRVTY
| Q4 25 | 31.5% | 21.0% | ||
| Q3 25 | 18.6% | 17.2% | ||
| Q2 25 | 3.9% | 16.0% | ||
| Q1 25 | -5.7% | 16.9% | ||
| Q4 24 | 20.2% | 20.5% | ||
| Q3 24 | 27.4% | 18.4% | ||
| Q2 24 | 10.4% | 19.7% | ||
| Q1 24 | -5.0% | 20.0% |
资本支出强度LIIRVTY
| Q4 25 | 2.4% | 2.6% | ||
| Q3 25 | 2.5% | 2.6% | ||
| Q2 25 | 1.9% | 2.6% | ||
| Q1 25 | 2.4% | 2.4% | ||
| Q4 24 | 4.5% | 3.4% | ||
| Q3 24 | 2.8% | 3.3% | ||
| Q2 24 | 2.3% | 3.2% | ||
| Q1 24 | 2.8% | 2.7% |
现金转化率LIIRVTY
| Q4 25 | 2.50× | 1.85× | ||
| Q3 25 | 1.22× | 2.97× | ||
| Q2 25 | 0.31× | 2.49× | ||
| Q1 25 | -0.30× | 3.03× | ||
| Q4 24 | 1.68× | 1.84× | ||
| Q3 24 | 1.89× | 1.57× | ||
| Q2 24 | 0.75× | 2.87× | ||
| Q1 24 | -0.18× | 5.67× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
LII
| Residential Heating And Cooling | $699.8M | 59% |
| Commercial Heating And Cooling | $495.2M | 41% |
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
